Receptor based drug design now plays a major role in the drug discovery. It may be applied to drug design depends highly on the availability of the receptor information. Systematic identification of protein-drug interaction networks is crucial to correlate complex modes of drug action to clinical indications and is applied to drug design when receptor structure is identified or characterized by high-resolution X-ray crystallography, NMR spectroscopy techniques or electron cryomicroscopy. The X-ray structures of a receptor and ligand-receptor complex provide greater and also some useful information about the binding cavity. Since binding sites of the receptor are very stereospecific so ligand or the drug molecule is modified in silico to achieve a better fit of the drug molecule to the binding site. This type of ligand modification is carried out by using sophisticated molecular modeling softwares. Especially by combinatorial chemistry drug synthesis is carried out in highly efficient manner and in larger quantities also. Trial and error approach of the ancient time is now totally changed. The aim is to achieve a better and novel drug that bind to its particular receptor.
Cite this article:
Sandip N. Badeliya, Dhrubo Jyoti Sen. Bioreceptor Platform: A Macromolecular Bed for Drug Design. Asian J. Research Chem. 3(4): Oct. - Dec. 2010; Page 812-820.
Sandip N. Badeliya, Dhrubo Jyoti Sen. Bioreceptor Platform: A Macromolecular Bed for Drug Design. Asian J. Research Chem. 3(4): Oct. - Dec. 2010; Page 812-820. Available on: https://ajrconline.org/AbstractView.aspx?PID=2010-3-4-1